KDR and pulmonary arterial hypertension: These adverse effects include EC dysfunction, apoptosis, and impaired angiogenesis, partly through inhibition of vascular endothelial growth factor receptor 2 (VEGFR2), contributing to systemic and pulmonary hypertension (42, 43).